Squarepoint Ops LLC Sells 23,122 Shares of CureVac (NASDAQ:CVAC)

Squarepoint Ops LLC lessened its stake in CureVac (NASDAQ:CVAC) by 59.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 16,043 shares of the company’s stock after selling 23,122 shares during the period. Squarepoint Ops LLC’s holdings in CureVac were worth $55,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in CVAC. BNP Paribas Financial Markets bought a new stake in shares of CureVac in the fourth quarter valued at about $585,000. Two Sigma Investments LP bought a new stake in shares of CureVac in the fourth quarter valued at about $391,000. Alyeska Investment Group L.P. lifted its stake in shares of CureVac by 25.0% in the fourth quarter. Alyeska Investment Group L.P. now owns 500,000 shares of the company’s stock valued at $1,705,000 after buying an additional 100,000 shares during the period. Northern Trust Corp lifted its stake in shares of CureVac by 98.1% in the fourth quarter. Northern Trust Corp now owns 60,100 shares of the company’s stock valued at $205,000 after buying an additional 29,759 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of CureVac by 10.3% in the fourth quarter. Geode Capital Management LLC now owns 241,750 shares of the company’s stock valued at $824,000 after buying an additional 22,491 shares during the period. Institutional investors own 17.26% of the company’s stock.

Analyst Ratings Changes

CVAC has been the subject of several recent research reports. JMP Securities reissued a “market outperform” rating and issued a $10.00 price target on shares of CureVac in a research report on Wednesday, May 28th. UBS Group dropped their price target on shares of CureVac from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Wednesday, April 30th.

CureVac Price Performance

Shares of CVAC stock opened at $4.27 on Wednesday. CureVac has a 52-week low of $2.37 and a 52-week high of $5.00. The stock has a market cap of $957.92 million, a PE ratio of 7.76 and a beta of 2.49. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The firm’s 50 day moving average price is $3.62 and its two-hundred day moving average price is $3.44.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings results on Thursday, May 22nd. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.08). The firm had revenue of $0.94 million for the quarter, compared to the consensus estimate of $4.27 million. CureVac had a return on equity of 21.98% and a net margin of 20.72%. As a group, analysts forecast that CureVac will post 0.72 EPS for the current year.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.